Eagle Wealth Advisors LLC Sells 808 Shares of Eli Lilly and Company $LLY

Eagle Wealth Advisors LLC trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 35.8% in the 1st quarter, HoldingsChannel.com reports. The fund owned 1,448 shares of the company’s stock after selling 808 shares during the period. Eli Lilly and Company comprises 1.2% of Eagle Wealth Advisors LLC’s holdings, making the stock its 17th biggest position. Eagle Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,332,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $25,000. Osbon Capital Management LLC purchased a new position in Eli Lilly and Company during the 4th quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC increased its stake in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares during the last quarter. Basso Capital Management L.P. bought a new stake in Eli Lilly and Company in the 4th quarter worth approximately $30,000. Finally, 10Elms LLP raised its holdings in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research reports. HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their target price for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Guggenheim restated a “buy” rating and issued a $1,183.00 target price on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Finally, Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,235.07.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Several bullish articles highlighted Eli Lilly’s strong GLP-1 momentum, with coverage pointing to continued upside in Mounjaro/Zepbound and new support from Medicare’s expanded access for GLP-1 weight-loss drugs, which could broaden demand and strengthen the company’s long-term growth outlook.
• Positive Sentiment: Analyst commentary and price-target pieces remained constructive, with one report arguing Lilly still has double-digit upside and another noting multiple analysts are leaning bullish ahead of earnings, reinforcing the market’s confidence in the company’s fundamentals.
• Neutral Sentiment: Lilly and Innovent announced a commercialization agreement for Verzenios in mainland China, which should help expand access and keep Lilly’s manufacturing role intact, but the deal mainly shifts marketing and distribution responsibilities rather than materially changing the company’s core earnings profile.
• Neutral Sentiment: Lilly also received attention for a new AI-related investment and for broader optimism around its pipeline, including retatrutide and other next-generation obesity treatments, which support the long-term growth narrative but are not immediate catalysts.
• Negative Sentiment: Shares were weighed by reports that U.S. lawmakers opened a national security probe into Lilly’s clinical trial activities in China, creating regulatory and reputational uncertainty around its operations in the region.
• Negative Sentiment: There was also fresh concern over China patent risk, including a report that Hybio filed what was described as the first generic challenge to Lilly’s tirzepatide patents, raising the possibility of future competition or legal friction around a key blockbuster drug.

Eli Lilly and Company Stock Down 0.6%

NYSE LLY opened at $1,192.16 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,238.00. The firm has a market capitalization of $1.12 trillion, a price-to-earnings ratio of 42.35, a PEG ratio of 1.49 and a beta of 0.51. The company has a fifty day moving average of $1,053.61 and a two-hundred day moving average of $1,025.60.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts predict that Eli Lilly and Company will post 35.74 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.